Korro Bio, Inc.
NCM: KRROLive Quote
About Korro Bio, Inc.
Healthcare
Biotechnology
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
📊 Fundamental Analysis
Korro Bio, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -43.1% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -110.7%, which indicates that capital utilization is currently under pressure.
At a current price of $12.68, KRRO currently trades near the bottom of its 52-week range (15%), indicating potential value or weakness (Range: $5.20 - $55.89).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$157.78M
Trailing P/E
--
Forward P/E
-1.67
Beta (5Y)
2.43
52W High
$55.89
52W Low
$5.20
Avg Volume
250K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App